Výsledky vyhledávání - "David E. Watson"

Akademický článek

Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experimental chronic hepatitis B and persistent occult hepadnaviral infection

Autor: Christopher P. Corkum, Louisa L. Wiede, Cara L.-A. Ruble, Jiabin Qiu, Patricia M. Mulrooney-Cousins, Meredith A. Steeves, David E. Watson, Tomasz I. Michalak

Publikováno v: Frontiers in Microbiology, Vol 13 (2022)

Woodchuck (Marmota monax) infected with woodchuck hepatitis virus (WHV) is the most pathogenically compatible naturally occurring model of human hepatitis B virus (HBV) infection, chronic hepatitis B, and HBV-induced hepatocellular carcinoma. This sy

Externí odkaz: https://doaj.org/article/3540bc6b9c5b47518ad3a62312db74a3

Zobrazit plný text záznamu

Evaluating Associations Between Nonclinical Cardiovascular Functional Endpoints and Repeat-dose Cardiovascular Toxicity in the Beagle Dog: A Cross-company Initiative

Autor: Adam Hargreaves, Rob Wallis, Derek J. Leishman, Louise Leong, Steven Engle, Lorna Ewart, David E. Watson, Kathleen M. Heinz-Taheny, Philip H. Milliken, Nick McMahon, Sarah Kirk, Peter Clements, Mike Aylott, Jean-Pierre Valentin, Magali Guffroy, Renaud Fleurance, Nick Edmunds

Publikováno v: Toxicological Sciences. 176:224-235

Integrating nonclinical in vitro, in silico, and in vivo datasets holistically can improve hazard characterization and risk assessment. In pharmaceutical development, cardiovascular liabilities are a leading cause of compound attrition. Prior to clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2764b1583d31e2aea76a3e12dabc3e8
https://doi.org/10.1093/toxsci/kfaa051

Zobrazit plný text záznamu

Akademický článek

Cloning and Assembly of PCR Products Using Modified Primers and DNA Repair Enzymes

Autor: David E. Watson, George N. Bennett

Publikováno v: BioTechniques, Vol 23, Iss 5, Pp 858-864 (1997)

We present a method for the creation of ligatable 3′overhangs by the incorporation of a modified base, uracil, at a specific position in the PCR primer and subsequent treatment with the DNA-modifying enzyme uracil DNA glycosylase and then either T4

Externí odkaz: https://doaj.org/article/087b4eb6867c4d3590053499856249a6

Zobrazit plný text záznamu

Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies

Autor: David E. Watson, Ayad K. Ali

Publikováno v: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 37:1383-1390

tudy Objective Ipilimumab, pembrolizumab, and nivolumab are checkpoint inhibitors (CPIs) that activate T-cell–mediated immune response. CPI can provide durable benefits to some cancer patients with melanoma, renal cell cancer, non–small cell lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93082c9058ccf5ac9084cf8b410b7d57
https://doi.org/10.1002/phar.2035

Zobrazit plný text záznamu

Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology

Autor: John P. Wikswo, David E. Watson, Rosemarie Hunziker

Publikováno v: Experimental Biology and Medicine. 242:1559-1572

Microphysiological systems (MPS), which include engineered organoids (EOs), single organ/tissue chips (TCs), and multiple organs interconnected to create miniature in vitro models of human physiological systems, are rapidly becoming effective tools f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7065dd35e385550eda350c0803d8d96
https://doi.org/10.1177/1535370217732765

Zobrazit plný text záznamu

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

Publikováno v: Experimental Biology and Medicine. 242:1579-1585

Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these chips have the potential to increase the predictive power of preclinical modeling, which in turn will move the pharmaceutical industry closer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3128a14f0b4ce35a220ee4e7ecd5eeff
https://doi.org/10.1177/1535370217715441

Zobrazit plný text záznamu

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Autor: Ronan P Kelly, Parag Garhyan, David E. Moller, Thomas Hardy, Christof M. Kazda, Mark A. Deeg, Ying Ding, Haoda Fu, David E. Watson, William H. Landschulz, Chay Ngee Lim, Chunxue Shi, Andrew Lewin

Publikováno v: Diabetes Care. 39:1241-1249

OBJECTIVE Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d3b5ddd435e965bdc29f0a0a121d11e
https://doi.org/10.2337/dc15-1643

Zobrazit plný text záznamu

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Autor: Chunxue Shi, William H. Landschulz, David E. Moller, David E. Watson, Thomas Hardy, Ying Ding, Mark A. Deeg, Christof M. Kazda, Haoda Fu, Chay Ngee Lim, Ronan P Kelly, Parag Garhyan, Andrew Lewin

Publikováno v: Diabetes care. 39(11)

We appreciate the thoughtful comments raised by Agrawal and Gupta (1) on our recent article (2) on the efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. We are pleased that they acknowledge that this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb836c6e668da4b8c19fed37f295b96
https://pubmed.ncbi.nlm.nih.gov/27926897

Zobrazit plný text záznamu

Biomarkers of Exocrine Pancreatic Injury in 2 Rat Acute Pancreatitis Models

Autor: Amy L. Usborne, John Morris Sullivan, Aaron T. Smith, Jennie L. Walgren, Steven K. Engle, David E. Watson

Publikováno v: Toxicologic Pathology. 42:195-203

Consistent, sensitive biomarkers of exocrine pancreatic injury (EPIJ) in animal models and humans have historically represented a poorly met need for investigators and clinicians. Experimental design: Sprague-Dawley CD/International Genetic Standard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9ab763d43579905ea4fbcbfae6bd61
https://doi.org/10.1177/0192623313512030

Zobrazit plný text záznamu

FutureTox III: Bridges for Translation

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology. 155(1)

Future Tox III, a Society of Toxicology Contemporary Concepts in Toxicology workshop, was held in November 2015. Building upon Future Tox I and II, Future Tox III was focused on developing the high throughput risk assessment paradigm and taking the s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c4236e3a78690937c3ddb410ac9870
https://pubmed.ncbi.nlm.nih.gov/27780885

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání